The pulmonary embolism market reached a value of USD 1.9 Billion across the top 7 markets (US, EU4, UK, and Japan) in 2024. Looking forward, IMARC Group expects the top 7 major markets to reach USD 3.6 Billion by 2035, exhibiting a growth rate (CAGR) of 5.88% during 2025-2035.

While the PE market of 2025 continues to evolve with respect to the advancements in technologies embraced by healthcare systems, there are increased incidences that need to be dealt with. The condition pulmonary embolism, wherein blood clots obstruct lung arteries, requires expert and prompt evaluation alongside effective management due to its potential mortal nature. This article delves into emerging trends within the market, reasons contributing towards increasing incidence numbers along with advances in technology which are changing diagnostics and therapeutic options in a reader-friendly manner.

Diagnostic imaging techniques like CT pulmonary angiography as well as V/Q scans will continue to play an essential role in Medicine even in the year 2025 but there would be a marked improvement on non-invasive approaches at the point of care ultrasound testing level especially for emergency rooms. During these times, hospitals and urgent care facilities will make use of portable ultrasound equipments for faster detection while D-dimer tests (blood assays measuring levels of clot breakdown products) will gain popularity due to their convenience, cost effectiveness and rapid processing time.In the therapeutic area, there is a notable increase in the uptake and demand of direct oral anticoagulants (DOACs). With the treatment of Deep Vein Thrombosis (DVT) no longer being limited to injections or warfarin therapy, DOACs are now preferred. Their adoption is amplified by the global population aging trends alongside increased patient-centric approaches as global demographic shifts prioritize convenience with less monitoring or dietary restrictions. Additionally, emerging biologics and novel agents under development offer tailored therapies for complicated DVT cases.

Request a PDF Sample Report: https://www.imarcgroup.com/pulmonary-embolism-market/requestsample

Reasons Contributing To Increased Incidences Of Pulmonary Embolism

A convergence of medical and demographic trends across numerous regions is expected to escalate the volume of pulmonary embolism cases. Sedentary lifestyles coupled with obesity, and pre-existing chronic health conditions like cancer and cardiovascular diseases add to the risk. The elderly population, vulnerable to clot formation along with various other enduring disorders also adds strain to these existing conditions, making these patients more susceptible than ever.

Enhanced clinician focus on complex cases combined with advanced widespread sensitive diagnostic tools has led to increased accuracy in identified pulmonary embolism (PE) cases. While improving case resolution certainly brings positive changes, it inadvertently increases systemic workload due to a rising detection prevalence—be it mild incidental or acute severe cases that require sustained attention.

Market Outlook and Future Directions

Strategically speaking, the pulmonary embolism market is expected to see further growth starting in 2025. There have been collaborations between diagnostic imaging companies and artificial intelligence developers as the latter seeks to incorporate machine learning into clinical workflows. Investment from pharmaceutical companies has been directed toward trials for injectable biologic agents and more advanced anticoagulants. Low-risk PE patients are now being treated within their homes due to enhancements in outpatient management systems by healthcare providers.

The report also provides a detailed analysis of the current pulmonary embolism marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug overview

• Mechanism of action

• Regulatory status

• Clinical trial results

• Drug uptake and market performance
   

Late-Stage Pipeline Drugs

• Drug overview

• Mechanism of action

• Regulatory status

• Clinical trial results

• Drug Uptake and Market Performance

Competitive Landscape:

The competitive landscape of the pulmonary embolism market has been studied in the report with the detailed profiles of the key players operating in the market.

Bristol-Myers Squibb/Pfizer
Daiichi Sankyo, Inc.
GlaxoSmithKline
Johnson & Johnson
Translational Sciences, Inc.

7 Major Countries Covered

United States
Germany
France
United Kingdom
Italy
Spain
Japan

About Us:

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact US:

IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
United States: +1-631-791-1145